Benjamin Halladay - Mar 14, 2024 Form 4 Insider Report for Esperion Therapeutics, Inc. (ESPR)

Role
Chief Financial Officer
Signature
/s/ Sheldon L. Koenig, by power of attorney
Stock symbol
ESPR
Transactions as of
Mar 14, 2024
Transactions value $
$0
Form type
4
Date filed
3/15/2024, 04:32 PM
Previous filing
Mar 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ESPR Common Stock Award $0 +170K +229.93% $0.00 244K Mar 14, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ESPR Stock Option (right to buy) Award $0 +200K $0.00 200K Mar 14, 2024 Common Stock 200K $2.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2024.